Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Neurogene Logo
Neurogene Growth Score
79
CB Rank
6724
Heat Score
95
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.neurogene.com/
Biotechnology
Overview

Neurogene
Total Funding
obfuscation
Growth Score
79
Heat Score
95

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score79
2 pts
in past quarter
Heat Score 95
27 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Neurogene

CB Rank
6724
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.neurogene.com/
Biotechnology

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series B
OBF
in
obfuscation

Key People

Details

Legal Name Neurogene Inc.
Operating Status Active
Stock Symbol  NASDAQ:NGNE
Company Type For Profit
Founders  Rachel McMinn
About the Company

Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that

improves quality of life.

Diversity Spotlight 
Women Founded
Women Led
Predictions & Insights

Growth Insight

See this Growth Insight
Neurogene is
Lorem
 to be growing
Top Contributing Factors
Financial Decline

Products & Services

NGN-101
A gene therapy product in clinical development for treating CLN5 Batten disease, a rare neurodegenerative disorder in children.
NGN-401
A gene therapy product in clinical development for treating Rett syndrome, a neurological disorder.

Research & Development

Neurogene is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Redmile Group Logo
Redmile Group
—
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
Redmile Group Logo
Redmile Group
—
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
Redmile Group Logo
Redmile Group
—
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
Redmile Group Logo
Redmile Group
—
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—
Redmile Group Logo
Redmile Group
—
Post-IPO Equity - Neurogene Logo
Post-IPO Equity - Neurogene
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 5 Board Members and Advisors 3 Contacts 70

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,245
-88.47%
 in past month

IT Spend

$20.1KThis year, Neurogene is projected to spend $20.1K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Independent Broker-Dealer Logo
Independent Broker-Dealer
88
Meta Platforms, Inc. Logo
Meta Platforms, Inc.
87
Fortune Logo
Fortune
86

Actively Used Products

8Neurogene uses 8 technology products and services including Wordpress, Google Tag Manager, and  Adobe Fonts, according to G2 Stack.

Active Website Tech Count

5Neurogene is actively using 5 technologies for its website, according to BuiltWith. These include Viewport Meta, reCAPTCHA, and  CommonCrawl Top 5m.

Total IP

8Neurogene has 1 registered patent in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Neurogene has registered 7 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Neurogene's headquarters? Neurogene is located in New York, New York, United States.Who invested in Neurogene? Neurogene has 14 investors including Redmile Group and  Samsara BioCapital.When was the last funding round for Neurogene? Neurogene closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Neurogene's competitors? Alternatives and possible competitors to Neurogene may include LEXEO Therapeutics, Zevra Therapeutics, and  Mahzi Therapeutics.How much funding has Neurogene raised to date? Neurogene has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(6ec160d 1)
|